Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
OXFORD - Pfizer (NYSE:PFE) has published findings showing that Oxford BioDynamics’ EpiSwitch blood-based biomarkers effectively evaluate tumor status and treatment outcomes in bladder cancer patients, according to a press release issued Tuesday.
The study, published in the journal Cancers, analyzed data from 496 patients in the JAVELIN Bladder 100 Trial and found that EpiSwitch biomarkers in blood samples strongly correlate with immune profiles of patient tumors.
Researchers from multiple institutions, including Pfizer’s Computational Biology team, St. Bartholomew’s Hospital in London, and Dana-Farber Cancer Institute, collaborated on the study. Their findings indicate that the EpiSwitch technology can determine whether a tumor has high or low immune activity, which is crucial for making informed cancer treatment decisions.
"The results from the published Pfizer study are a powerful endorsement for our blood-based biomarker EpiSwitch technology," said Dr. Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics.
The study demonstrates that EpiSwitch biomarkers could potentially serve as a less invasive alternative to traditional tissue biopsies for monitoring cancer patients. This technology provides insights into the body’s immune response to cancer through a blood test rather than requiring tissue samples.
Oxford BioDynamics’ EpiSwitch technology is already being used in prostate cancer testing. The company’s EpiSwitch PSE test for early prostate cancer detection has shown 94% accuracy compared to 55% for standard PSA testing, according to the company.
The JAVELIN Bladder 100 Trial previously demonstrated a significant survival benefit with avelumab maintenance plus best supportive care versus best supportive care alone in bladder cancer patients.
Oxford BioDynamics is traded on London’s AIM market under the ticker OBD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.